MoonLake Investors Face Dec. 15 Lead‑Plaintiff Deadline in Securities Suits Tied to SLK Trial Collapse

Overview

• National plaintiffs’ firms including Bronstein, Bragar Eagel & Squire, Berger Montague, and Rosen are urging MoonLake shareholders to seek lead‑plaintiff status by December 15, 2025.
• The actions cover investors who bought MoonLake stock between March 10, 2024 and September 29, 2025, as outlined in recent notices.
• The complaints allege MoonLake promoted sonelokimab as superior despite sharing IL‑17A and IL‑17F targets with UCB’s BIMZELX and lacking evidence of clinical superiority.
• MoonLake’s September 29, 2025 Form 8‑K reported VELA‑2 failed to achieve statistical significance at week 16, citing intercurrent events in a higher‑than‑expected placebo arm.
• MoonLake shares fell about 89–90% on September 29, 2025 following the disclosure, and the litigation remains in early stages with no class yet certified.